Lorundrostat is an aldosterone inhibitor associated with greater reductions in 24 hour average blood pressure than placebo in patitients with uncontrolled and treatment resistant hypertension.
Lorundrostat is a highly selective aldosterone synthase inhibitor directly targeting aldosterone biosynthesis.
Lorundrostat is a selective aldosterone synthase inhibitor developed for the treatment of uncontrolled and treatment-resistant hypertension.
When added to existing antihypertensive regimens, significantly reduces systolic blood pressure in adults who do not achieve adequate control with other medications.
Lorundrostat works by directly inhibiting aldosterone synthesis, reducing the hormone’s production, which addresses one of the central mechanisms behind resistant hypertension.
Unlike traditional mineralocorticoid receptor antagonists, lorundrostat spares other adrenal steroid pathways, potentially reducing issues like compensatory aldosterone increases and side effects associated with broader steroid inhibition.
Lorundrostat is usually dosed at 50 mg/day, with potential uptitration to 100 mg, produces statistically significant reductions in systolic blood pressure compared to placebo, even among patients taking multiple antihypertensives.
Blood pressure improvements in lorundrostat groups ranged from a reduction of 6.5 to 16.9 mm Hg over placebo, with benefits observed regardless of demographic factors such as race or gender.
It is generally well tolerated; hyperkalemia and hyponatremia were observed but were infrequently severe, and adverse events were more common at the higher dose without added efficacy.
There is a need for serum potassium and sodium monitoring, especially in patients with impaired renal function.
Lorundrostat expands therapeutic options for patients whose hypertension is not controlled with existing treatments by targeting aldosterone biosynthesis directly.
By inhibiting aldosterone production it spares other adrenal steroid pathways with fewer adverse effects.